Cleveland BioLabs, Inc.
73 High Street
Buffalo,
NY 14203
United States - Map
Phone: 716-849-6810
Fax: 716-849-6820
Web Site: http://www.cbiolabs.com
| Cleveland Biolabs, Inc. engages in the discovery, development, and commercialization of products for cancer treatment and protection of normal tissues from radiation and other acute stresses. The companys products include Protectan CBLB502, a radioprotectant molecule with multiple medical and defense applications for reducing injury from acute stresses, such as radiation and chemotherapy by mobilizing various natural cell protecting mechanisms, including inhibition of apoptosis, reduction of oxidative damage, and induction of factors that induce protection and regeneration of stem cells in bone marrow and intestine; Protectan CBLB612, a modified lipopeptide mycoplasma that acts as a stimulator and mobilizer of hematopoietic stem cells to peripheral blood, providing hematopoietic recovery during chemotherapy and during donor preparation for bone marrow transplantation; and Curaxins, which include a first generation anticancer agent that demonstrated activity and safety in a Phase II clinical trial and an enhanced second generation compound that is entering formal pre-clinical development. Cleveland Biolabs has a strategic research partnership with Roswell Park Cancer Institute to develop its cancer and radioprotectant drug candidates; has a strategic partnership with ChemBridge Corporation to access a chemical library of 214,000 compounds, as well as to jointly manage the development and commercialization of compounds arising from selected projects; and has a collaborative relationship with the Armed Forces Radiobiology Research Institute. The company was founded in 2003 and is headquartered in Buffalo, New York. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Michael Fonstein Ph.D., 50
Co-founder, Chief Exec. Officer, Pres, Member of Management Board |
$
243.00K | N/A | Dr. Yakov N. Kogan Ph.D.,M.B.A, 36
Co-Founder, Chief Operating Officer, Sec. |
$
217.00K | N/A | Dr. Andrei V. Gudkov Ph.D., D.Sci., 53
Co-founder, Chief Scientific Officer |
$
0 | N/A | Mr. John A. Marhofer Jr., CMA, CFM, M.B.A., 47
Chief Financial Officer, Principal Accounting Officer, Gen. Mang. and Controller |
$
165.00K | N/A | Dr. George R. Stark Ph.D., FRS,
Co-Founder and Chairman of Scientific Advisory Board |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.07% Nasdaq 
0.005 (0.15%) 
Profile
